Clinical trials: Neoplasm, Breast
Breast Cancer, Breast Neoplasm
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
The purpose of this study is to evaluate the clinical benefit rate at 12 weeks from the addition of pazopanib to a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) in patients with hormone receptor positive…
- Trial name
- NCT01466972
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hope Rugo, MD
Breast Cancer, Breast Cancer Female
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
In this double blinded randomized placebo-controlled trial, 160 subjects scheduled for breast surgery involving the axilla will be administered a multimodal pain regimen including acetaminophen, dexamethasone, celecoxib, and…
- Conditions
- Breast Cancer, Breast Cancer Female, Cancer of Breast
- Trial name
- NCT03084536
- Testing
- Bupivacaine, Gabapentin, Celecoxib
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Washington University School of Medicine
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Breast Cyst
Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.
The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation.
- Trial name
- NCT03475992
- Testing
- Low-power microwave breast imaging system
- Where
- Ireland
- Volunteers
- 25 people
- Sponsor
- MVG Industries SAS
Breast Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of continued administration of paclitaxel given weekly in subjects considered to need to continue treatment after completion of the preceding "Phase II Clinical…
- Trial name
- NCT00971945
- Testing
- Paclitaxel
- Where
- 4 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Bristol-Myers Squibb
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes…
- Trial name
- PATINA (NCT02947685)
- Testing
- palbociclib, trastuzumab, pertuzumab
- Where
- 108 sites in United States, Australia and 6 more
- Volunteers
- 518 people
- Sponsor
- Alliance Foundation Trials, LLC.
Breast Cancer
Patient-Assisted Compression - Impact on Image Quality and Workflow
This study is being conducted to compare the image quality of breast images obtained using standard (technologist-controlled [TC]) compression and patient-assisted (PA) compression and to evaluate the impact of PA compression on…
- Trial name
- NCT03196635
- Testing
- Patient-Assisted (PA) Breast Compression, Technologist-Controlled (TC) Breast Compression
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- GE Healthcare
Breast Cancer
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
- Trial name
- NCT03983382
- Testing
- Left Ventricular Ejection Fraction
- Where
- 8 sites in United States
- Volunteers
- 190 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- ISNA-Sein (NCT00462696)
- Testing
- Neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut Bergonié
Breast Cancer
Combination Chemotherapy for Metastatic Breast Cancer
The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer
- Trial name
- NCT00191815
- Testing
- Gemcitabine, cisplatin
- Where
- 2 sites in Germany, Russia
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT02498613
- Testing
- 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Study of E7389 for Advanced or Metastatic Breast Cancer
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred…
- Trial name
- NCT00965523
- Testing
- Eribulin Mesylate
- Where
- 5 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Eisai Co., Ltd.
Breast Cancer, Sentinel Lymph Node
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
The purpose of this study is to compare the effectiveness four different pain treatments for the injection of radioactive tracer that women with breast cancer receive for sentinel lymph node biopsies.
- Conditions
- Breast Cancer, Sentinel Lymph Node, Breast Neoplasms, Breast Cancer Female
- Trial name
- NCT04822597
- Testing
- Lidocaine patch, Buzzy(R), Ice pack
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2.
- Trial name
- NCT00232479
- Testing
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Miami
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Breast Carcinoma
Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer.
- Trial name
- NCT07216274
- Testing
- QT Ultrasound Breast Scanner, Questionnaire Administration
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
Natriuretic Peptide Concentrations of B-type (BNP) During Anesthesia in Patients Previously Sensitized to Anthracyclines
The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical and echocardiographic monitoring. In the case of treatment for breast cancer, surgery requiring general anesthesia may follow…
- Trial name
- PEP-NAT-B (NCT01754597)
- Testing
- Dosage of B-type natriuretic peptide (NT-proBNP)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Institut Bergonié
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.